{"entity":{"id":"nct06572813","kind":"trial","name":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer","aka":["CISPD-7"],"tldr":"A phase 1/2 trial of sintilimab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting.","summary":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06572813 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 63 participants, started 2024-11-15 and due to reach its primary completion in 2026-09-01. Interventions recorded: Bortezomib Injection; Sintilimab; mFOLFIRINOX. Conditions listed: Pancreas Cancer. Primary outcome: Phase 1: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0; Phase 2: Objective reponse rate (ORR). Pancreatic eligibility wording from the registry: \"* Pathologically (histologically or cytologically) confirmed pancreatic ductal adenocarcinoma (PDAC)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06572813","url":"https://clinicaltrials.gov/study/NCT06572813"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["sintilimab","folfirinox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06572813","phase":"1/2","setting":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for First-line Treatment of Metastatic Pancreatic Cancer：An Exploratory Clinical Trial","sponsor":"First Affiliated Hospital of Zhejiang University","enrolled":63,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06572813/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}